Skip to main content

Month: December 2020

Saniona minskar sin ägarandel i Scandion Oncology till under 5 procent som ett resultat av Scandions framgångsrika företrädesemission

PRESSMEDDELANDE16 december 2020Saniona minskar sin ägarandel i Scandion Oncology till under 5 procent som ett resultat av Scandions framgångsrika företrädesemissionSaniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, tillkännager idag att företaget minskar sin ägarandel i Scandion Oncology A/S (Spotlight Stock Market: SCOL) till under 5 procent. Minskningen är ett resultat av den företrädesemission som Scandion Oncology genomförde 15 december 2020.Scandion Oncology bildades 2017 genom en avknoppning av tillgångar från Saniona. I tillgångarna ingick SCO-101, en first-in-class molekyl inriktad mot kemoterapiresistens, tillsammans med besläktade molekyler och teknisk kompetens.För mer information, vänligen kontaktaTrista Morrison, Chief Communications Officer, Saniona. Kontor: + 1 (781)...

Continue reading

Signify proposes to re-appoint Gerard van de Aast as Supervisory Board member

Press ReleaseDecember 16, 2020Signify proposes to re-appoint Gerard van de Aast as Supervisory Board memberEindhoven, the Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, will propose to re-appoint Gerard van de Aast as Supervisory Board member for a tenure of four years at the Annual General Meeting of Shareholders (AGM) to be held in 2021.Gerard van de Aast has been a member of the Supervisory Board since 2017. He is Vice chair of the Supervisory Board, Chair of the Remuneration Committee and member of the Audit Committee.More information about Signify’s 2021 AGM will be published in due course. Additional information on Signify’s Board of Management and Supervisory Board can be found here.— END —  For further information, please contact:Signify Investor RelationsRogier DierckxTel: +31 6 1138 4609E-mail:...

Continue reading

Riber: Order for a research MBE machine in Asia 

Bezons, December 16, 2020 – 8:00 am – RIBER, global market leader in MBE equipment for semiconductor industry, is announcing an order for a research system in Asia.RIBER received an order for a research system, model C21 DZ, from a leading academic research group in Asia. This system will be used primarily to prepare ultra-pure layers of III-V materials for low-temperature transport studies, including quantum Hall Effect measurements.The ordered system will be delivered in 2021.About RIBERRIBER is the global market leader in MBE equipment. The company designs and produces molecular beam epitaxy (MBE) systems as well as evaporation sources and cells for the semiconductor industry. It also provides technical and scientific support for its clients, maintaining their equipment and optimizing their performance and output levels. Through its...

Continue reading

RIBER : Commande d’une machine MBE de recherche en Asie

Bezons, le 16 décembre 2020 – 08h00 – RIBER, leader mondial d’équipement MBE pour l’industrie des semi-conducteurs, annonce la commande d’un système de recherche en Asie.RIBER a reçu une commande pour un système de recherche, modèle MBE C21 DZ, d’un centre de recherche universitaire de premier plan en Asie. Ce système sera principalement utilisé pour la préparation de couches ultrapures de matériaux III-V pour étudier leurs propriétés de transport à basse température, incluant les mesures quantiques d’effet Hall.Le système commandé sera livré en 2021.A propos de RIBERRIBER est le leader mondial d’équipement MBE (épitaxie par jets moléculaires). L’entreprise conçoit et fabrique des systèmes MBE ainsi que des évaporateurs destinés à l’industrie des semi-conducteurs. Elle offre également à ses clients un support technique et scientifique...

Continue reading

Annual decisions made on planning for crisis management of Swedish banks

Nine Swedish banks conduct systemically important operations and therefore must be managed through a particular procedure, resolution, in the event of a crisis. This assessment is made by the Swedish National Debt Office in the resolution plans on which it has now decided.The Debt Office periodically analyses the institutions’ (banks’) functions and their importance for the financial system. The analysis is summarised in so-called resolution plans, which set out how every individual bank should be managed if a crisis were to occur.For systemically important banks, which are critical to the essential functioning of the financial system and could significantly disrupt it if they were to fail, the Debt Office plans for resolution. Through resolution, the central government assumes control of the bank in crisis and keeps it open while it...

Continue reading

NB Private Equity: Publishes Investor Presentation

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONSNB Private Equity Partners Publishes Investor Presentation16 December 2020NB Private Equity Partners Limited (“NBPE” or the “Company”) today published a new presentation for the previously announced investor update scheduled for Wednesday 16 December 2020.The webinar will take place at 13.00 GMT / 14.00 CET / 8.00 EST.  The call can be accessed via the Zoom call details below:Join from a PC, Mac, iPad, iPhone or Android device:Please click this URL to join. https://nb.zoom.us/s/91373094346?pwd=UFpIT3c4cU8weXRXWG81ZExSaWtDUT09Webinar ID: 913 7309 4346Passcode: 564319Or join by phone:    Dial (for higher quality, dial a number based on your current...

Continue reading

New special share-based incentive programme

Company AnnouncementCopenhagen, 16 December 2020No. 26/2020ISS A/S (ISS.CO, ISS DC, ISSDY), a leading workplace experience and facility management company, has today implemented a new special share-based incentive programme (the “SIP”).The SIP is a programme that serves as a tool for general retention and project execution purposes.Participants under the SIP will be granted a number of restricted share units (“RSUs”) which entitle the participant, subject to vesting occurring, to receive a number of existing shares in the Company without payment of any consideration, equal to the integral number of RSUs vested which have not lapsed.The RSUs under the SIP will be subject to a vesting period as determined by the Board of Directors at grant. The vesting period for the initial grants under the SIP will cover the period from the...

Continue reading

GreenMobility publishes prospectus for listing on Nasdaq Copenhagen Main Market

Company Announcement no. 76 – 2020Copenhagen, December 16th, 2020GreenMobility publishes prospectus for listing on Nasdaq Copenhagen Main MarketWith reference to company announcement no. 69 dated 7 October 2020, no. 74 dated 11 December and no. 75 dated 15 December 2020, GreenMobility A/S (“GreenMobility”) today announces the publication of its listing prospectus which has been approved by the Danish Financial Supervisory Authority (the “Listing Prospectus”) for the admission to trading and official listing of GreenMobility’s shares on Nasdaq Copenhagen Main Market (the “Listing”).A link to the Listing Prospectus can be found below in this announcement. Additionally a copy is available at www.greenm.dk, and physical copies may be obtained within business hours at the offices of GreenMobility at Landgreven 3, 4th floor, 1301 Copenhagen...

Continue reading

AB Science announces that Phase 2B/3 study evaluating oral in Alzheimer’s disease met its primary endpoint

PHASE 2B/3 STUDY EVALUATING MASITINIB IN ALZHEIMER’S DISEASE MET ITS PRIMARY ENDPOINTMASITINIB DEMONSTRATED SIGNIFICANT EFFECT ON BOTH COGNITION, MEASURED WITH ADAS-COG, AND DAILY ACTIVITY, MEASURED WITH ADCS-ADLAB SCIENCE WILL HOST A LIVE WEBCAST ON DECEMBER 17, 2020 – 11am-12am EST; 5pm-6pm CET WITH KEY OPINION LEADERS TO FURTHER DISCUSS THE RESULTSParis, December 16, 2020, 8am CETAB Science SA (Euronext – FR0010557264 – AB) today announced that the Phase 2B/3 study (AB09004 – NCT01872598) evaluating oral masitinib in patients with mild and moderate Alzheimer’s disease met its predefined primary endpoint.Study AB09004 was an international, randomized, placebo-controlled, phase 2B/3 study evaluating different doses of masitinib as a treatment of patients with confirmed mild to moderate Alzheimer’s disease. This...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.